Publikationen

2025 – 2020

2025

Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOP

Cetin O, Kos IA, Regitz E, Bewarder M, Rixecker TM, Tausch E, Schwarz EC, Jansky J, Lesan V, Schormann C, Neumann F, Loeffler M, Hallek MJ, Fischer K, Zophel S, Staiger AM, Ott G, Christofyllakis K, Bittenbring JT, Poeschel V, Kaddu-Mulindwa D, Staber PB, Ligtvoet R, Robrecht S, Ziepert M, Schmitz N, Hoth M, Kessel C, Stilgenbauer S, Altmann B, Thurner L
Blood Adv. 2025 Dec 8:bloodadvances.2025016931
PMID: 41358738 DOI: 10.1182/bloodadvances.2025016931

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Othman Al-Sawaf, M.D., Ph.D., Janina Stumpf, M.D., Can Zhang, Ph.D., Florian Simon, M.D., Francesc Bosch, M.D., Ph.D., Emadoldin Feyzi, M.D., Paolo Ghia, M.D., Ph.D., Michael Gregor, M.D., Arnon P. Kater, M.D., Ph.D., Vesa Lindström, M.D., Mattias Mattsson, M.D., Carsten U. Niemann, M.D., Ph.D., Philipp B. Staber, M.D., Ph.D., Tamar Tadmor, M.D., Patrick Thornton, M.D., Clemens-Martin Wendtner, M.D., Ph.D., Ann Janssens, M.D., Thomas Noesslinger, M.D., Jan-Paul Bohn, M.D., Ph.D., Caspar da Cunha-Bang, M.D., Ph.D., Christian B. Poulsen, M.D., Juha Ranti, M.D., Thomas Illmer, M.D., Bjoern Schoettker, M.D., Sebastian Böttcher, M.D., Tobias Gaska, M.D., Elisabeth Vandenberghe, M.D., Ruth Clifford, M.D., Ph.D., Ohad Benjamini, M.D., Anna Maria Frustaci, M.D., Lydia Scarfò, M.D., Paolo Sportoletti, M.D., John Schreurs, M.D., Mark-David Levin, M.D., Hanneke van der Straaten, M.D., Marjolein van der Klift, M.D., Hoa Tran, M.D., Javier de la Serna, M.D., Javier Loscertales, M.D., Oscar Lindblad, M.D., Anna Bergendahl Sandstedt, M.D., Jeroen Goede, M.D., Michael Baumann, M.D., Anna Maria Fink, M.D., Kirsten Fischer, M.D., Matthias Ritgen, M.D., Karl-Anton Kreuzer, M.D., Christof Schneider, M.D., Eugen Tausch, M.D., Stephan Stilgenbauer, M.D., Sandra Robrecht, Ph.D., Barbara Eichhorst, M.D., and Michael Hallek, M.D., for the CLL17 Trial Investigators
DOI: https://doi.org./10.1056/NEJMoa2515458

Efficacy of MRD-triggered Anti-CD20 Retreatment in Patients with High-Risk Chronic Lymphocytic Leukemia: A Case Series

Ellinor Goergen, Sandra Robrecht, Rudy Ligtvoet, Kirsten Fischer, Barbara F. Eichhorst, Petra Langerbeins, Michael J Hallek; Blood Advances 2025
PMID: 40921002 DOI: 10.1182/bloodadvances.2025017109

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza, Sandra Robrecht, Julia von Tresckow, Anna Fink, Florian Simon, Eugen Tausch, Christof Schneider, Liliya Sivcheva, Anthony P. Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Gunnar Juliusson, Caspar da Cunha-Bang, Thomas Illmer, Michael Gregor, Patrick Thornton, Ann Janssens, Tamar Tadmor, Vesa Lindstrom, Philipp B. Staber, Mark-David Levin, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Stephan Stilgenbauer, Arnon P. Kater, Carsten Utoft Niemann, Kirsten Fischer, Barbara F. Eichhorst, Michael J Hallek; Blood 2025
PMID: 40864973 DOI: 10.1182/blood.2025028899

Acalabrutinib treatment in Older (≥80y) and/or Frail Patients with CLL – Primary Endpoint Analysis of the CLL-Frail Trial

Florian Simon, Rudy Ligtvoet, Jan-Paul Bohn, Thomas Nösslinger, Julia von Tresckow, Rüdiger Liersch, Tobias Gaska, Kathleen Jentsch-Ulrich, Michael Gärtner, Thomas Wolff, Ingo Schwaner, Dominik Wolf, Christof Schneider, Ursula Vehling-Kaiser, Matthias Ritgen, Christian Spoer, Michael J. Eckart, Thomas Decker, Geothy Chakupurakal, Björn Schöttker, Jens Kisro, Karl-Anton Kreuzer, Eugen Tausch, Stephan Stilgenbauer, Sandra Robrecht, Janina Stumpf, Anna Fink, Moritz Fürstenau, Kirsten Fischer, Valentin Goede, Michael J Hallek, Barbara F. Eichhorst; Blood 2025
PMID: 40906922 DOI: 10.1182/blood.2025028550

Surrogate endpoints in mature B-cell neoplasms – meaningful or misleading?

Florian Simon, Othman Al-Sawaf, John F. Seymour, Barbara Eichhorst
Leukemia. 2025; 39(1): 25–28. Published online 2024 Dec 10. doi: 10.1038/s41375-024-02483-5
PMCID: PMC11717702
Article PDF–576K

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia

Valentin Goede, Kirsten Fischer, Sandra Robrecht, Adam Giza, Martin J. S. Dyer, Michael J. Eckart, Lothar Mϋller, Lukáš Smolej, Nadine Kutsch, Anna-Maria Fink, Stephan Stilgenbauer, Michael Hallek
Blood Adv. 2025 May 27; 9(10): 2431–2435. Published online 2025 Mar 20. doi: 10.1182/bloodadvances.2024014875
PMCID: PMC12142505
Article PDF–552K

Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy

Hallek M.Am J Hematol. 2025 Mar;100(3):450-480. doi: 10.1002/ajh.27546. Epub 2025 Jan 28. Free PMC article. Review.
PMID: 39871707

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Langerbeins P, Robrecht S, Nieper P, Cramer P, Fürstenau M, Al-Sawaf O, Simon F, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Schneider C, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Zahn MO, Dörfel S, Staib P, Behlendorf T, Hensel M, Hebart H, Klaproth H, Block A, Liersch R, Hauch U, Heinrich B, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M.J Clin Oncol. 2025 Feb;43(4):392-402. doi: 10.1200/JCO.24.00975. Epub 2024 Nov 27. Clinical Trial.
PMCID: 39602678

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, Fürstenau M, Goede V, von Tresckow J, Langerbeins P, Fink AM, Huber H, Tausch E, Schneider C, Wendtner CM, Ritgen M, Dreyling M, Müller L, Jacobasch L, Heinz WJ, Vehling-Kaiser U, Sivcheva L, Böttcher S, Dreger P, Illmer T, Gregor M, Staber PB, Stilgenbauer S, Niemann CU, Kater AP, Fischer K, Eichhorst B, Hallek M, Al-Sawaf O.J Clin Oncol. 2025 Feb;43(4):381-391. doi: 10.1200/JCO.24.01192. Epub 2024 Aug 23. Free PMC article.
PMID: 39213466

MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial.

Fürstenau M, Robrecht S, Schneider C, Tausch E, Giza A, Ritgen M, Bittenbring JT, Hebart H, Schöttker B, Illert ALL, Graeven U, Stoltefuss A, Heinrich B, Eckert R, Fink AM, Stumpf J, Fischer K, Al-Sawaf O, Simon F, Kleinert F, Weiss J, Kreuzer KA, Schilhabel A, Brüggemann M, Langerbeins P, Stilgenbauer S, Eichhorst B, Hallek MJ, Cramer P.Blood. 2025 Jan 30:blood.2024026685. doi: 10.1182/blood.2024026685. Online ahead of print.
PMID: 39883943

2024

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial

J Clin Oncol. 2024 Nov 27:JCO2400975. doi: 10.1200/JCO.24.00975. Online ahead of print.

PMID: 39602678

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Blood (2024) 144 (Supplement 1): 4613. doi: 10.1182/blood-2024-208727

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Sivchev L, Niemann CU, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Manzoor BS, Jawaid D, Emechebe N, Devine J, Boyer M, Runkel ED, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K.

Blood. 2024 Oct 31;144(18):1924-1935. doi: 10.1182/blood.2024024631.

PMID: 39082668

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia

J Clin Oncol. 2024 Aug 23:JCO2401192. doi: 10.1200/JCO.24.01192. Online ahead of print.

PMID: 39213466

Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia

Lewis RI, Vom Stein AF, Hallek M.

Blood. 2024 Aug 8;144(6):601-614. doi: 10.1182/blood.2023022861

PMID: 38776510

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combination

Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kater AP, van der Spek E, Niemann CU, da Cunha-Bang C, Tausch E, Schneider C, Stilgenbauer S, Fischer K, Hallek M, Eichhorst B.

Am J Hematol. 2024 Aug;99(8):1620-1623. doi: 10.1002/ajh.27367. Epub 2024 May 17.

PMID: 38757754

Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry

Kutsch N, Giza A, Robrecht S, Stumpf J, Federhen A, Stoltefuß A, Vehling-Kaiser U, Koenigsmann M, Tausch E, Schneider C, Stilgenbauer S, Illmer T, Schlag R, Dörfel S, Gaska T, Kiehl M, Müller-Hagen S, Moorahrend E, Linde H, Schlenska-Lange A, von Tresckow J, Fischer K, Eichhorst B, Hallek M, Fink AM.

Eur J Haematol. 2024 Aug;113(2):235-241. doi: 10.1111/ejh.14220. Epub 2024 May 1.

PMID: 38693677

The role of trephine bone marrow biopsies in the era of measurable residual disease-Results from the CLL10 trial of the German CLL Study Group (GCLLSG)

Kutsch N, Robrecht S, Fink A, Lange E, Weide R, Kiehl MG, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Clausen MR, Oschlies I, Ritgen M, Herling M, Fischer K, Döhner H, Wendtner CM, Kreuzer KA, Stilgenbauer S, Hallek M, Böttcher S, Klapper W, Eichhorst B.

Hemasphere. 2024 Jul 24;8(7):e126. doi: 10.1002/hem3.126. eCollection 2024 Jul.

PMID: 39050548

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.

Fürstenau M, Giza A, Weiss J, Kleinert F, Robrecht S, Franzen F, Stumpf J, Langerbeins P, Al-Sawaf O, Simon F, Fink AM, Schneider C, Tausch E, Schetelig J, Dreger P, Böttcher S, Fischer K, Kreuzer KA, Ritgen M, Schilhabel A, Brüggemann M, Stilgenbauer S, Eichhorst B, Hallek M, Cramer P.

Blood. 2024 Jul 18;144(3):272-282. doi: 10.1182/blood.2023022730.

PMID: 38620072

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B.

Lancet Oncol. 2024 Jun;25(6):744-759. doi: 10.1016/S1470-2045(24)00196-7.

PMID: 38821083

Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.

Mellinghoff SC, Robrecht S, Sprute R, Mayer L, Weskamm LM, Dahlke C, Gruell H, Teipel F, Schlößer HA, Siepmann K, Thelen M, Fink AM, Fischer K, Klein F, Addo MM, Kolovou A, Cornely OA, Eichhorst B, Hallek M, Langerbeins P.
Eur J Haematol. 2024 May;112(5):788-793. doi: 10.1111/ejh.14170. Epub 2024 Feb 4.

PMID: 38311570

Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.

Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kutsch N, Simon F, Goede V, Hoechstetter MA, Niemann CU, da Cunha-Bang C, Kater AP, Dubois J, Gregor M, Staber PB, Tausch E, Schneider C, Stilgenbauer S, Eichhorst B, Fischer K, Hallek MJ.
Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564. Online ahead of print.
PMID: 38620092

Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.

PMID: 38620072

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.

Cramer P, von Tresckow J, Fink AM, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, Langerbeins P, Fischer K, Kreuzer KA, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M.
Am J Hematol. 2024 Apr 5. doi: 10.1002/ajh.27304. Online ahead of print.

PMID: 38578022

Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, Schetelig J, von Tresckow J, Vehling-Kaiser U, Gaska T, Wendtner CM, Chapuy B, Fischer K, Kreuzer KA, Stilgenbauer S, Staber P, Niemann C, Hallek M, Eichhorst B.

Nat Med. 2024 Jan;30(1):240-248. doi: 10.1038/s41591-023-02722-9. Epub 2023 Dec 9.

PMID: 38071379

Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease

Stumpf J, Al-Sawaf O.
Curr Oncol Rep. 2024 Jan 4. doi: 10.1007/s11912-023-01482-6. Epub ahead of print.

PMID: 38175465

2023

Hengeveld PJ, van der Klift MY, Kolijn PM, Davi F, Kavelaars FG, de Jonge E, Robrecht S, Assmann JLJC, van der Straten L, Ritgen M, Westerweel PE, Fischer K, Goede V, Hallek M, Levin MD, Langerak AW

Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.

Blood. 2023 Feb 2; 141(5):519-528 doi: 10.1182/blood.2022017411. PMID: 36084320

Stachelscheid J, Jiang Q, Aszyk C, Warner K, Bley N, Müller T, Vydzhak O, Symeonidis K, Crispatzu G, Mayer P, Blakemore SJ, Goehring G, Newrzela S, Hippler S, Robrecht S, Kreuzer KA, Pallasch C, Krüger M, Lechner A, Fischer K, Stilgenbauer S, Beutner D, Hallek M, Auguin D, Hüttelmaier S, Bloehdorn J, Vasyutina E, Herling M

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.

Blood. 2023 Mar 23; 141(12):1425-1441 doi: 10.1182/blood.2022015494. PMID: 36179280

Kutsch N, Holmes EE, Robrecht S, Schüler G, Vehling-Kaiser U, Decker T, Müller-Hagen S, Heinisch K, Böttcher S, Ritgen M, Kreuzer KA, Stilgenbauer S, Fink AM, Fischer K, Eichhorst B, Hallek M, Wendtner CM

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.

Leuk Lymphoma. 2023 Feb; 64(2):478-482 doi: 10.1080/10428194.2022.2148210. Epub 2022 Nov 24. PMID: 36423347 No abstract available

Jiang Q, Stachelscheid J, Bloehdorn J, Pacholewska A, Aszyk C, Grotenhuijs F, Müller T, Onder O, Wagle P, Herling CD, Kleppe M, Wang Z, Coombes KR, Robrecht S, Dalvi PS, Plosnita B, Mayer P, Abruzzo LV, Altmüller J, Gathof B, Persigehl T, Fischer K, Jebaraj B, Rienhoff HY, Ecker R, Zhao Y, Bruns CJ, Stilgenbauer S, Elenitoba-Johnson K, Hallek M, Schweiger MR, Odenthal M, Vasyutina E, Herling M

Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

Blood. 2023 Jul 6; 142(1):44-61 doi: 10.1182/blood.2022017230. PMID: 37023372

Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson JN, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K.

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

Nat Commun. 2023 Apr 18; 14(1):2147 doi: 10.1038/s41467-023-37648-w. PMID: 37072421

Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M; GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

N Engl J Med. 2023 May 11; 388(19):1739-1754 doi: 10.1056/NEJMoa2213093. PMID: 37163621 Clinical Trial

Fürstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AM, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber PB, Tadmor T, Levin MD, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Janssens A, Christiansen I, Nösslinger T, Baumann M, Hebart H, Gaska T, Regelink JC, Dompeling EC, Lindström V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink AM, Fischer K, Wendtner CM, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann CU, Hallek M, Eichhorst B, Kreuzer KA, Kater AP

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Blood. 2023 Aug 3; 142(5):446-459 doi: 10.1182/blood.2023019634. PMID: 37172204 Clinical Trial

Hallek M.

First line therapy of CLL.

Hematol Oncol. 2023 Jun; 41 Suppl 1:129-135 doi: 10.1002/hon.3145. PMID: 37294974

Al Sawaf O.

Importance of MRD in the era of targeted therapies in CLL

Acta Haematol. 2023 Oct 30. doi: 10.1159/000534846. Epub ahead of print. PMID: 37903476

von Tresckow J, Heyl N, Robrecht S, Giza A, Aldaoud A, Schlag R, Klausmann M, Linde H, Stein W, Schwarzer A, Fischer K, Cramer P, Eichhorst B, Hallek M, Fink AM

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group

Ann Hematol. 2023 Nov; 102(11):3083-3090 doi: 10.1007/s00277-023-05314-2. Epub 2023 Jun 26. PMID: 37358640+

Huber H, Tausch E, Schneider C, Edenhofer S, von Tresckow J, Robrecht S, Giza A, Zhang C, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Dürig J, Böttcher S, Niemann CU, Kneba M, Al-Sawaf O, Kreuzer KA, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S.

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.

Blood. 2023 Sep 14; 142(11):961-972 doi: 10.1182/blood.2023020013. PMID: 37363867

Fink A.

Long-term efficacy of ibrutinib-venetoclax for first-line treatment in chronic lymphocytic leukaemia

Lancet Oncol. 2023 Dec; 24(12):1294-1295 doi: 10.1016/S1470-2045(23)00485-0. Epub 2023 Nov 6. PMID: 37944540

Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.

Nat Med. 2023 Dec 9. doi: . doi: 10.1038/s41591-023-02722-9. Online ahead of print. PMID: 38071379

Al-Sawaf O, Davids MS.

Overcoming Resistance in Chronic Lymphocytic Leukemia – Maybe Less is More?

Clin Cancer Res. 2023 Dec 6 doi: 10.1158/1078-0432.CCR-23-2872. Epub ahead of print. PMID: 38055246.

Vom Stein AF, Hallek M, Nguyen PH.

Role of the tumor microenvironment in CLL pathogenesis.

Semin Hematol. 2023 Dec 26:S0037-1963(23)00098-7 doi: 10.1053/j.seminhematol.2023.12.004. Online ahead of print. PMID: 38220499

Stumpf J, Al-Sawaf O.

Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease

Curr Oncol Rep. 2024 Jan 4. doi: 10.1007/s11912-023-01482-6. Epub ahead of print. PMID: 38175465.

2022

Kutsch N, Pallasch C, Tausch E, Böhme V, Ritgen M, Liersch R, Wacker A, Jacobs G, Trappe RU, Dreger P, Fischer K, Fink AM, Stilgenbauer S, Zhai S, Li B, Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M, Eichhorst BF.

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.

Hemasphere. 2022 Mar 8 doi: 10.1097/HS9.0000000000000692. PMID: 35284802

Huber H, Edenhofer S, von Tresckow J, Robrecht S, Zhang C, Tausch E, Schneider C, Bloehdorn J, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Dürig J, Böttcher S, Niemann CU, Kneba M, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S.

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.

Blood. 2022 Mar 3 doi: 10.1182/blood.2021013208. PMID: 35108374

Kaddu-Mulindwa D, Altmann B, Robrecht S, Ziepert M, Regitz E, Tausch E, Held G, Poeschel V, Lesan V, Bittenbring JT, Thurner L, Pfreundschuh M, Christofyllakis K, Truemper L, Loeffler M, Schmitz N, Hoth M, Hallek M, Fischer K, Stilgenbauer S, Bewarder M, Rixecker TM.

KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.

Lancet Haematol. 2022 Feb doi: 10.1016/S2352-3026(21)00369-0. PMID: 35114151

Mellinghoff SC, Robrecht S, Mayer L, Weskamm LM, Dahlke C, Gruell H, Vanshylla K, Schlösser HA, Thelen M, Fink AM, Fischer K, Klein F, Addo MM, Eichhorst B, Hallek M, Langerbeins P.

SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia.

Leukemia. 2022 Feb doi: 10.1038/s41375-021-01500-1. PMID: 34937858

Al-Sawaf O, Hallek M, Fischer K.

The role of minimal residual disease in chronic lymphocytic leukemia.

Clin Adv Hematol Oncol. 2022 Feb. PMID: 35120090

Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M.

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.

Blood. 2022 Jan 13 doi: 10.1182/blood.2021010845. PMID: 34758069

Sharman JP,Biondo JML, Boyer M, Fischer K, Hallek M, Jiang D, Kater AP, Porro Lurà M, Wierda WG

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies

EJHaem. 2022 Apr 5; 3(2):492-506 doi: 10.1002/jha2.427. eCollection 2022 May. PMID: 35846043

Kutsch N, Pallasch C, Decker T, Hebart H, Chow KU, Graeven U, Kisro J, Kroeber A, Tausch E, Fischer K, Fink AM, Wendtner CM, Ritgen M, Stilgenbauer S, Zhang D, Li B, Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M, Eichhorst B

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.

Hemasphere. 2022 May 25; 6(6):e729 doi: 10.1097/HS9.0000000000000729. eCollection 2022 Jun. PMID: 35747845

Langerbeins P, Hallek M.

COVID-19 in patients with hematologic malignancy.

Blood. 2022 Jul 21; 140(3):236-252 doi: 10.1182/blood.2021012251. PMID: 35544585

Rusyn L, Reinartz S, Nikiforov A, Mikhael N, Vom Stein A, Kohlhas V, Bloehdorn J, Stilgenbauer S, Lohneis P, Buettner R, Robrecht S, Fischer K, Pallasch C, Hallek M, Nguyen PH, Seeger-Nukpezah T

The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia.

Leukemia. 2022 Jul; 36(7):1794-1805 doi: 10.1038/s41375-022-01586-1. Epub 2022 May 6. PMID: 35523865

Samineni D, Gibiansky L, Wang B, Vadhavkar S, Rajwanshi R, Tandon M, Sinha A, Al-Sawaf O, Fischer K, Hallek M, Salem AH, Li C, Miles D

Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.

Adv Ther. 2022 Aug; 39(8):3635-3653 doi: 10.1007/s12325-022-02170-w. Epub 2022 Jun 16. PMID: 35708885

von Tresckow J, Cramer P, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Fürstenau M, Illmer T, Klaproth H, Tausch E, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst BF, Hallek M.

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial

Leukemia. 2022 Aug; 36(8):2125-2128 doi: 10.1038/s41375-022-01629-7. Epub 2022 Jun 25. PMID: 35752657

Fürstenau M, Weiss J, Giza A, Franzen F, Robrecht S, Fink AM, Fischer K, Schneider C, Tausch E, Stilgenbauer S, Ritgen M, Schilhabel A, Brüggemann M, Eichhorst B, Hallek M, Cramer P.

Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.

Clin Cancer Res. 2022 Oct 3; 28(19):4203-4211 doi: 10.1158/1078-0432.CCR-22-0433. PMID: 35594173 Clinical Trial

Schilhabel A, Walter PJ, Cramer P, von Tresckow J, Kohlscheen S, Szczepanowski M, Laqua A, Fischer K, Eichhorst B, Böttcher S, Schneider C, Tausch E, Brüggemann M, Kneba M, Hallek M, Ritgen M

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis

Cancers (Basel). 2022 Oct 7; 14(19):4917 doi: 10.3390/cancers14194917. PMID: 36230840

Cramer P, Fürstenau M, Robrecht S, Giza A, Zhang C, Fink AM, Fischer K, Langerbeins P, Al-Sawaf O, Tausch E, Schneider C, Schetelig J, Dreger P, Böttcher S, Kreuzer KA, Schilhabel A, Ritgen M, Brüggemann M, Kneba M, Stilgenbauer S, Eichhorst B, Hallek M

Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.

Lancet Haematol. 2022 Oct; 9(10):e745-e755 doi: 10.1016/S2352-3026(22)00211-3. Epub 2022 Aug 18 PMID: 35988545 Clinical Trial

Kutsch N, Fink AM, Fischer K

Management of front line chronic lymphocytic leukemia.

Am J Hematol. 2022 Nov; 97 Suppl 2:S3-S10 doi: 10.1002/ajh.26677. PMID: 36125035

Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling CD, Nieper P, Feldmann T, Merkel O, Lorsy E, da Palma Guerreiro A, von Jan J, Kisis I, Wasserburger E, Claasen J, Faitschuk-Meyer E, Altmüller J, Nürnberg P, Yang TP, Lienhard M, Herwig R, Kreuzer KA, Pallasch CP, Büttner R, Schäfer SC, Hartley J, Abken H, Peifer M, Kashkar H, Knittel G, Eichhorst B, Ullrich RT, Herling M, Reinhardt HC, Hallek M, Schweiger MR, Frenzel LP

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

Blood. 2022 Nov 17; 140(20):2113-2126 doi: 10.1182/blood.2021014304. PMID: 35704690

Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, Tausch E, Delgado J, Barbera-Mourelle A, Taylor-Weiner A, Bousquets-Muñoz P, Diaz-Navarro A, Dunford A, Anand S, Kretzmer H, Gutierrez-Abril J, López-Tamargo S, Fernandes SM, Sun C, Sivina M, Rassenti LZ, Schneider C, Li S, Parida L, Meissner A, Aguet F, Burger JA, Wiestner A, Kipps TJ, Brown JR, Hallek M, Stewart C, Neuberg DS, Martín-Subero JI, Puente XS, Stilgenbauer S, Wu CJ, Campo E, Getz G

Molecular map of chronic lymphocytic leukemia and its impact on outcome

Nat Genet. 2022 Nov; 54(11):1664-1674 doi: 10.1038/s41588-022-01140-w. Epub 2022 Aug 4. PMID: 35927489

Simon F, Giza A, Robrecht S, Fink AM, Cramer P, von Tresckow J, Fürstenau M, Goede V, Tausch E, Schneider C, Stilgenbauer S, Wendtner CM, Eichhorst B, Fischer K, Hallek M, Al-Sawaf O

Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older.

Leuk Lymphoma. 2022 Dec; 63(14):3299-3306 doi: 10.1080/10428194.2022.2123223. Epub 2022 Sep 18. PMID: 36120898

2021

Al-Sawaf O, Fischer K

TP53 mutations in CLL: does frequency matter?

Blood. 2021 Dec 23 doi: 10.1182/blood.2021012343. PMID: 34940820

Hallek M, Al-Sawaf O.

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.

Am J Hematol. 2021 Dec 1 doi: 10.1002/ajh.26367.PMID: 34625994

Fischer K, Al-Sawaf O.

Acalabrutinib monotherapy in patients with Richter transformation.

Lancet Haematol. 2021 Dec doi: 10.1016/S2352-3026(21)00334-3. Epub 2021 Nov 1.PMID: 34735861

Fürstenau M, Giza A, Stumpf T, Robrecht S, Maurer C, Linde H, Jacobasch L, Dörfel S, Aldaoud A, von Tresckow J, Koenigsmann M, Gaska T, Kaiser U, Harich HD, Fischer K, Eichhorst B, Hallek M, Fink AM.

Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.

Am J Hematol. 2021 Dec 1 doi: 10.1002/ajh.26363. Epub 2021 Oct 8.PMID: 34591989

Pflug N, Chakupurakal G, Fink A, Robrecht S, Herling M, Cramer P, Holtick U, Theurich S, Schetelig J, Fischer K, Ritgen M, Scheid C, Eichhorst B, Dreger P, Hallek M, Bergwelt-Baildon M

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies

Hemasphere 2021 Nov 12 doi: 10.1097/HS9.0000000000000664 PMID: 34881358

The CLL12 trial: Ibrutinib versus placebo in treatment-naïve, early stage chronic lymphocytic leukemia.

Blood. 2021 Nov 10 doi: 10.1182/blood.2021010845. Online ahead of print.PMID: 34758069

Kajüter H, Wellmann I, Khil L, Jöckel KH, Zhang C, Fink AM, Hallek M, Stang A.

Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany.

Blood Cancer J. 2021 Oct 29 doi: 10.1038/s41408-021-00556-7.PMID: 34716290

Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, Ching T, Tandon M, Fink AM, Tausch E, Schneider C, Ritgen M, Böttcher S, Kreuzer KA, Chyla B, Miles D, Wendtner CM, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K.

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.

J Clin Oncol, 2021 Oct 28 doi: 10.1200/JCO.21.01181; PMID: 34709929

Al-Sawaf O, Gentile B, Devine J, Zhang C, Sail K, Tandon M, Fink AM, Kutsch N, Wendtner CM, Eichhorst B, Hallek M, Fischer K.

Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.

Am J Hematol. 2021 Sep 1 doi: 10.1002/ajh.26260. Epub 2021 Jun 22.PMID: 3405097

loehdorn J, Braun A, Taylor-Weiner A, Jebaraj BMC, Robrecht S, Krzykalla J, Pan H, Giza A, Akylzhanova G, Holzmann K, Scheffold A, Johnston HE, Yeh RF, Klymenko T, Tausch E, Eichhorst B, Bullinger L, Fischer K, Weisser M, Robak T, Schneider C, Gribben J, Dahal LN, Carter MJ, Elemento O, Landau DA, Neuberg DS, Cragg MS, Benner A, Hallek M, Wu CJ, Döhner H, Stilgenbauer S, Mertens D

Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.

Nat Commun. 2021 Sep 13;12(1):5395. doi: https://doi.org/10.1038/s41467-021-25403-y

Beckmann L, Berg V, Dickhut C, Sun C, Merkel O, Bloehdorn J, Robrecht S, Marc Seifert, da Palma Guerreiro A, Claasen J, Loroch S, Oliverio M, Underbayev C, Vaughn L, Thomalla D, Huelsemann M, Tausch E, Fischer K, Fink AM, Eichhorst B, Sickmann A, Wendtner CM, Stilgenbauer S, Hallek M, Wiestner A, Peiman Zahedi R, Frenzel L

MARCKS affects cell motility and response to BTK inhibitors in CLL

Blood. 2021 Mar 18: blood.2020009165. doi: 10.1182/blood.2020009165

Fürstenau M, Fink AM, Schilhabel A, Weiss J, Robrecht S, Eckert R, de la Serna J, Crespo M, Coscia M, Vitale C, Böttcher S, Weppner G, Ritgen M, Stilgenbauer S, Tausch E, Fischer K, Hallek M, Eichhorst B, Brüggemann M, Herling CD.Blood. 2021 Apr 22;137(16):2267-2271. doi: 10.1182/blood.2020008609.PMID: 33512465 Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial. Cramer P, Tresckow JV, Robrecht S, Bahlo J, Fürstenau M, Langerbeins P, Pflug N, Al-Sawaf O, Heinz WJ, Vehling-Kaiser U, Dürig J, Tausch E, Hensel M, Sasse S, Fink AM, Fischer K, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M.

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.

Haematologica. 2021 Feb 1 blood.2020010484. doi: 10.3324/haematol.2019.223693.PMID: 32107341

Cramer P, Tausch E, von Tresckow J, Giza A, Robrecht S, Schneider C, Fürstenau M, Langerbeins P, Al-Sawaf O, Pelzer BW, Fink AM, Fischer K, Wendtner CM, Eichhorst B, Kneba M, Stilgenbauer S, Hallek M

Durable Remissions Following Combined Targeted Therapy in Patients with CLL Harboring TP53 Deletions and/or Mutations

Blood. 2021 Jun 4 blood.2020010484. doi: 10.1182/blood.2020010484. Online ahead of print. PMID: 34086865

Al-Sawaf O, Gentile B, Devine J, Zhang C, Sail K, Tandon M, Fink AM, Kutsch N, Wendtner CM, Eichhorst B, Hallek M, Fischer K

Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial

Am J Hematol. 2021 May 29 doi: 10.1002/ajh.26260. Online ahead of print. PMID: 34050972

Bloehdorn J, Krzykalla J, Holzmann K, Gerhardinger A, Jebaraj BMC, Bahlo J, Humphrey K, Tausch E, Robrecht S, Mertens D, Schneider C, Fischer K, Hallek M, Döhner H, Benner A, Stilgenbauer S

Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients

Haematologica. 2021 Mar 18. doi: 10.3324/haematol.2020.251561. Online ahead of print.

2020

B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide

Blood. 2020 Dec 23:blood.2020008609. doi: 10.1182/blood.2020008609. Online ahead of print

Kohlhaas V, Blakemore SJ, Al-Maarri M, Nickel N, Pal M, Roth A, Hoevelmeyer N, Schäfer SC, Knittel G, Lohneis P, Nikolic M, Wiederstein JL, Franitza M, Georgomonolis T, Reinart N, Herling M, Herling CD, Hartmann E, Rosenwald A, Klapper W, Buettner R, Moia R, Rossi D, Boldorini R, Gaidano G, Frenzel LP, Reinhardt C, Brüning JC, Hallek M, Krüger M, Peifer M, Pallasch CP, Wunderlich FT

Active AKT signaling triggers CLL towards Richter’s transformation via over-activation of Notch1

Blood. 2020 Nov 2:blood.2020005734. doi: 10.1182/blood.2020005734. Online ahead of print.

Fischer K, Al-Sawaf O, Hallek M

Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):357-362. doi: 10.1182/hematology.2020000120.

Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U; ESMO Guidelines Committee

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Ann Oncol. 2020 Oct 19:S0923-7534(20)42469-X doi: 10.1016/j.annonc.2020.09.019. Online ahead of print.

Agathangelidis A et al.

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

Blood. 2020 Sep 29:blood.2020007039 doi: 10.1182/blood.2020007039. Online ahead of print.

Krause G, Hassenrück F, Hallek M

Relevant Cytokines in the B Cell Lymphoma Micro-Environment

Cancers (Basel). 2020 Sep 5;12(9):E2525 doi: 10.3390/cancers12092525

Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Lancet Oncol. 2020 Sep;21(9):1188-1200 doi: 10.1016/S1470-2045(20)30443-5.

Cramer P, von Tresckow J, Eichhorst B, Hallek M

Aktuelle Standards in der Diagnostik und Therapie der chronischen lymphatischen Leukämie

Dtsch Med Wochenschr. 2020 Aug;145(16):1139-1144 doi: 10.1055/a-1039-8472. Epub 2020 Aug 13

Barthel R, Fedorchenko O, Velmans T, Rosen N, Nguyen PH, Reinart N, Florin A, Herling M, Hallek M, Fingerle-Rowson G

CD74 is dispensable for development of chronic lymphocytic leukemia in Eµ-TCL1 transgenic mice

Leuk Lymphoma. 2020 Jul 15:1-12. doi: 10.1080/10428194.2020.1791851. Online ahead of print.

Fürstenau M, Langerbeins P, De Silva N, Fink AM, Robrecht S, von Tresckow J, Simon F, Hohloch K, Droogendijk J, van der Klift M, van der Spek E, Illmer T, Schöttker B, Fischer K, Wendtner CM, Tausch E, Stilgenbauer S, Niemann CU, Gregor M, Kater AP, Hallek M, Eichhorst B

COVID-19 among fit patients with CLL treated with venetoclax-based combinations

Leukemia. 2020 Aug;34(8):2225-2229 doi: 10.1038/s41375-020-0941-7. Epub 2020 Jun 29

Langerbeins P, Fürstenau M, Gruell H, Klein F, Persigehl T, Rybniker J, Seeger-Nukpezah T, Kochanek M, Hallek M, Eichhorst B, Koehler P, Böll B

COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia

Eur J Haematol 2020 Jun 23. doi: 10.1111/ejh.13475. Online ahead of print

Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Ekström Smedby K, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini ME, Cavalli F, Stuessi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foa R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D

International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia

Blood. 2020 May 21;135(21):1859-1869 doi: 10.1182/blood.2019003453

Awan FT, Al-Sawaf O, Fischer K, Woyach JA

Current Perspectives on Therapy for Chronic Lymphocytic Leukemia

Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-10. doi: 10.1200/EDBK_279099

Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, Bahlo J, Al-Sawaf O, Ritgen M, Fink AM, Eichhorst B, Kreuzer KA, Tandon M, Humphrey K, Jiang Y, Schary W, Bullinger L, Mertens D, Porro Lurà M, Kneba M, Döhner H, Fischer K, Hallek M, Stilgenbauer S

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood. 2020 Mar 23. pii: blood.2019004492. doi: 10.1182/blood.2019004492. [Epub ahead of print]

Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, V Tresckow J, Lange E, Kiehl M, Dreyling M, Ritgen M, Dürig J, Tausch E, Schneider C, Stilgenbauer S, Wendtner CM, Fischer K, Goede 5th, Hallek M, Eichhorst B

Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials

Leukemia. 2020 Mar 17. doi: 10.1038/s41375-020-0797-x. [Epub ahead of print]

Cramer P, V Tresckow J, Robrecht S, Bahlo J, Fürstenau M, Langerbeins P, Pflug N, Al-Sawaf O, Heinz WJ, Vehling-Kaiser U, Dürig J, Tausch E, Hensel M, Sasse S, Fink AM, Fischer K, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial

Haematologica. 2020 Feb 27. pii: haematol.2019.223693. doi: 10.3324/haematol.2019.223693. [Epub ahead of print]

Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C, De Silva N, Lange E, Weide R, Kiehl MG, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Herling M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Böttcher S, Stilgenbauer S, Fink AM, Hallek M, Eichhorst B

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

Hemasphere. 2020 Jan 27;4(1):e336. doi: 10.1097/HS9.0000000000000336. eCollection 2020 Feb.

Herling CD, Cymbalista F, Groß-Ophoff-Müller C, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Busch R, Porcher R, Cazin B, Dreyfus B, Ibach S, Leprêtre S, Fischer K, Kaiser F, Eichhorst B, Wentner CM, Hoechstetter MA, Döhner H, Leblond V, Kneba M, Letestu R, Böttcher S, Stilgenbauer S, Hallek M, Levy V

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial

Leukemia. 2020 Aug;34(8):2038-2050 doi: 10.1038/s41375-020-0747-7. Epub 2020 Feb 18

Al-Sawaf O, Eichhorst B, Hallek M

Chronische lymphatische Leukämie

Internist (Berl). 2020 Feb 11. doi: 10.1007/s00108-019-00733-8. [Epub ahead of print]

Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Bahlo J, Robrecht S, Eckart MJ, Vehling-Kaiser U, Jacobs G, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner C, Fischer K, Herling CD, Starck M, Bentz M, Emmerich B, Döhner H, Stilgenbauer S, Hallek M

Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

Leukemia. 2020 Apr;34(4):1038-1051 doi: 10.1038/s41375-020-0727-y. Epub 2020 Feb 10

Al-Sawaf O, Lilienweiss E, Bahlo J, Robrecht S, Fink AM, Patz M, Tandon M, Jiang Y, Schary W, Ritgen M, Tausch E, Stilgenbauer S, Eichhorst B, Fischer K, Hallek M, Kreuzer KA

High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia

Blood. 2020 Mar 12;135(11):866-870 doi: 10.1182/blood.2019003451

Agius R, Brieghel C, Andersen MA, Pearson AT, Ledergerber B, Cozzi-Lepri A, Louzoun Y, Andersen CL, Bergstedt J, von Stemann JH, Jørgensen M, Tang ME, Fontes M, Bahlo J, Herling CD, Hallek M, Lundgren J, MacPherson CR, Larsen J, Niemann CU

Machine learning can identify newly diagnosed patients with CLL at high risk of infection

Nat Commun. 2020 Jan 17;11(1):363 doi: 10.1038/s41467-019-14225-8

Yosifov DY, Idler I, Bhattacharya N, Reichenzeller M, Close V, Ezerina D, Scheffold A, Jebaraj BMC, Kugler S, Bloehdorn J, Bahlo J, Robrecht S, Eichhorst B, Fischer K, Weigel A, Busch H, Lichter P, Döhner H, Dick TP, Stilgenbauer S, Mertens D

Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL

Leukemia. 2020 Jan;34(1):115-127. doi: 10.1038/s41375-019-0513-x.

2019 – 2015

2019

Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, Bloehdorn J, Hoechstetter M, Fischer K, Eichhorst B, Goede V, Hallek M, Döhner H, Rosenquist R, Ghia P, Stamatopoulos K, Stilgenbauer S

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)

Haematologica. 2019 Dec 26. pii: haematol.2019.231027. doi: 10.3324/haematol.2019.231027. [Epub ahead of print]

Eichhorst B, Fürstenau M, Hallek M

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):482-489. doi: 10.1182/hematology.2019000070

Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV

Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study

Lancet Oncol. 2019 Nov;20(11):1576-1586doi: 10.1016/S1470-2045(19)30503-0. Epub 2019 Sep 30

Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O’Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M

Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia

Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):715-722.e6 doi: 10.1016/j.clml.2019.07.004. Epub 2019 Jul 15

Fürstenau M, Hopfinger G, Robrecht S, Fink AM, Al-Sawaf O, Langerbeins P, Cramer P, Tresckow JV, Maurer C, Kutsch N, Hoechstetter M, Dreyling M, Lange E, Kneba M, Stilgenbauer S, Döhner H, Hensel M, Kiehl MG, Jaeger U, Wendtner CM, Goede V, Fischer K, Bergwelt MV, Eichhorst B, Hallek M, Theurich S

Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy

Leukemia. 2020 Apr;34(4):1177-1181 doi: 10.1038/s41375-019-0630-6. Epub 2019 Nov 14.

Hallek M

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment

Am J Hematol. 2019 Nov;94(11):1266-128. doi: 10.1002/ajh.25595. Epub 2019 Oct 4

Fürstenau M, Hallek M, Eichhorst B

Sequential and combination treatments with novel agents in chronic lymphocytic leukemia

Haematologica. 2019 Nov;104(11):2144-2154doi: 10.3324/haematol.2018.208603

Fürstenau M, Bahlo J, Fink AM, Lange E, Dreger P, Dreyling M, Hess G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Wendtner CM, Goede V, Fischer K, Böttcher S, Hallek M, Eichhorst B

Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia

Leukemia. 2020 Mar;34(3):924-928 doi: 10.1038/s41375-019-0597-3. Epub 2019 Oct 14.

Jebaraj BMC, Tausch E, Landau DA, Bahlo J, Robrecht S, Taylor-Weiner AN, Bloehdorn J, Scheffold A, Mertens D, Böttcher S, Kneba M, Jäger U, Zenz T, Wenger MK, Fingerle-Rowson G, Wendtner C, Fink AM, Wu CJ, Eichhorst B, Fischer K, Hallek M, Döhner H, Stilgenbauer S

Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia

Leukemia. 2019 Sep;33(9):2183-2194 doi: 10.1038/s41375-019-0446-4. Epub 2019 Mar 25

Edelmann J, Holzmann K, Tausch E, Saunderson EA, Jebaraj BMC, Steinbrecher D, Dolnik A, Blätte TJ, Landau DA, Saub J, Estenfelder S, Ibach S, Cymbalista F, Leblond V, Delmer A, Bahlo J, Robrecht S, Fischer K, Goede V, Bullinger L, Wu CJ, Mertens D, Ficz G, Gribben JG, Hallek M, Döhner H, Stilgenbauer S

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1 regulated transcription

Haematologica. 2019 Aug 29. pii: haematol.2019.217307. doi: 10.3324/haematol.2019.217307. [Epub ahead of print]

Fürstenau M, De Silva N, Eichhorst B, Hallek M

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

Hemasphere. 2019 Aug 9;3(5):e287 doi: 10.1097/HS9.0000000000000287

Kreuzer KA, Furman RR, Stilgenbauer S, Dubowy RL, Kim Y, Munugalavadla V, Lilienweiss E, Reinhardt HC, Cramer P, Eichhorst B, Hillmen P, O’Brien SM, Pettitt AR, Hallek M

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

Leukemia. 2020 Jan;34(1):296-300 doi: 10.1038/s41375-019-0533-6. Epub 2019 Aug 19.

Fink AM

Is chemoimmunotherapy maintenance of value in patients with chronic lymphocytic leukaemia and minimal residual disease?

(Comment) Lancet Haematol. 2019 Sep;6(9):e441-e442 doi: 10.1016/S2352-3026(19)30107-3. Epub 2019 Jul 16

Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction

Cell. 2019 Jul 25;178(3):699-713.e19 doi: 10.1016/j.cell.2019.06.011. Epub 2019 Jul 4.

Al-Sawaf O, Bazeos A, Robrecht S, Bahlo J, Gower C, Fink AM, Tresckow JV, Cramer P, Langerbeins P, Kutsch N, Humphrey K, Fingerle-Rowson G, Stilgenbauer S, Wendtner CM, Fischer K, Eichhorst B, Hallek M, Goede V

Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)

Am J Hematol. 2019 Sep;94(9):1002-1006 doi: 10.1002/ajh.25561. Epub 2019 Jul 8.

Hallek M, Fürstenau M

How to approach CLL in clinical practice

Hematol Oncol. 2019 Jun;37 Suppl 1:38-42

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

N Engl J Med. 2019 Jun 6;380(23):2225-2236

Soumerai JD, Ni A, Xing G, Huang J, Furman RR, Jones J, Sharman JP, Hallek M, Adewoye AH, Dubowy R, Dreiling L, Zelenetz AD

Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials

Leuk Lymphoma. 2019 Jun;60(6):1438-1446 doi: 10.1080/10428194.2018.1540782. Epub 2018 Nov 8

Sachanas S, Pangalis GA, Fink AM, Bahlo J, Fischer K, Levidou G, Kyrtsonis MC, Bartzi V, Vassilakopoulos TP, Kalpadakis C, Koulieris E, Moschogiannis M, Yiakoumis X, Tsirkinidis P, Angelopoulou MK, Eichhorst B, Hallek M

Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in „Real-Life“ Outside of Clinical Trials

Anticancer Res. 2019 May;39(5):2591-2598

von Tresckow J, Cramer P, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Illmer T, Klaproth H, Estenfelder S, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst BF, Hallek M

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia

Leukemia. 2019 May;33(5):1161-1172 doi: 10.1038/s41375-018-0313-8

Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance

Leuk Lymphoma. 2019 Mar;60(3):649-657 doi: 10.1080/10428194.2018.1488253. Epub 2018 Sep 20

Schetelig J, Link CS, Stuhler G, Wagner EM, Hänel M, Kobbe G, Böttcher S, Kreuzer KA, Middeke JM, Sockel K, Teipel R, von Bonin M, Stölzel F, Kramer M, Stilgenbauer S, Hallek M, Bornhäuser M; Deutsche CLL Studiengruppe and the German Cooperative Transplant Study Group

Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial

Br J Haematol. 2019 Mar;184(5):833-836 doi: 10.1111/bjh.15181. Epub 2018 Mar 12

Tresckow JV, Eichhorst B, Bahlo J, Hallek M

The Treatment of Chronic Lymphatic Leukemia

Dtsch Arztebl Int. 2019 Jan 25;116(4):41-46

Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van Dongen JJM

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Blood. 2019 Jan 31;133(5):494-497 doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19

2018

Eichhorst B, Hallek M, Goede V

Management of unfit elderly patients with chronic lymphocytic leukemia

Eur J Intern Med. 2018 Dec;58:7-13. doi: 10.1016/j.ejim.2018.02.001. Review

Al-Sawaf O, Bahlo J, Robrecht S, Fischer K, Herling CD, Hoechstetter M, Fink AM, von Tresckow J, Langerbeins P, Cramer P, Stilgenbauer S, Wendtner CM, Eichhorst B, Hallek M, Goede V

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia

Br J Haematol. 2018 Dec;183(5):727-735 doi: 10.1111/bjh.15604. Epub 2018 Nov 21

Hallek M

On the architecture of translational research designed to control chronic lymphocytic leukemia

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):1-8

von Tresckow J, Hallek M, Eichhorst B

Individualisierte Therapie der chronischen lymphatischen Leukämie

Dtsch Med Wochenschr. 2018 Sep;143(18):1318-1324 doi: 10.1055/a-0550-2286. Epub 2018 Sep 10

Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, Engelke A, Fink AM, Fischer K, Tausch E, Seiler T, Fischer von Weikersthal L, Hebart H, Kreuzer KA, Böttcher S, Ritgen M, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

Lancet Oncol. 2018 Sep;19(9):1215-1228 doi: 10.1016/S1470-2045(18)30414-5. Epub 2018 Aug 13

Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance

Leuk Lymphoma. 2018 Sep 20:1-9 doi: 10.1080/10428194.2018.1488253. Epub 2018 Sep 20

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

J Clin Oncol. 2018 Jul 1;36(19):1973-1980 doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O’Brien S, Robak T, Seymour JF, Kipps TJ

iwCLL guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia

Blood. 2018 Jun 21;131(25):2745-2760 doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14

Hallek M, Shanafelt TD, Eichhorst B

Chronic lymphocytic leukaemia

Lancet. 2018 Apr 14;391(10129):1524-1537 Epub 2018 Feb 21.

Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, Fischer K, Eichhorst B, Goede V, van Dongen JJM, Ritgen M, Böttcher S, Langerak AW, Kneba M, Hallek M

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate endpoint in CLL

Blood. 2018 Mar 1;131(9):955-962 Epub 2017 Dec 18.

Cramer P, Tresckow JV, Bahlo J, Engelke A, Langerbeins P, Fink AM, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst B, Hallek M

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia

Future Oncol. 2018 Mar;14(6):499-513 doi: 10.2217/fon-2017-0442. Epub 2018 Feb 21.

van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, Kröger N; CLL subcommittee; Chronic Malignancies Working Party of the EBMT

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

Bone Marrow Transplant. 2018 Mar;53(3):255-263 doi: 10.1038/s41409-017-0023-2. Epub 2017 Dec 18.

Goede V, Hallek M

Welche hämato-onkologischen Medikamente sind im Alter entbehrlich oder ungeeignet?

Dtsch Med Wochenschr. 2018 Feb;143(4):244-252 doi: 10.1055/s-0043-106791. Epub 2018 Feb 22.

Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, Cartolano M, Oberbeck S, Mayer P, Berg V, Thomalla D, Kutsch N, Stiefelhagen M, Cramer P, Wendtner CM, Persigehl T, Saleh A, Altmüller J, Nürnberg P, Pallasch C, Achter V, Lang U, Eichhorst B, Castiglione R, Schäfer SC, Büttner R, Kreuzer KA, Reinhardt HC, Hallek M, Frenzel LP, Peifer M

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia

Nat Commun. 2018 Feb 20;9(1):727

Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL

Nat Commun. 2018 Feb 15;9(1):697

Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, Estenfelder S, Wang J, Edelmann J, Strefford JC, Wojdacz TK, Fischer K, Hallek M, Stilgenbauer S, Cragg M, Gribben J, Braun A

Lamin B1 regulates somatic mutations and progression of B-cell malignancies

Leukemia. 2018 Feb;32(2):364-375

Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E

Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project

Cytometry B Clin Cytom. 2018 Jan;94(1):121-128

Wolf C, Garding A, Filarsky K, Bahlo J, Robrecht S, Becker N, Zucknick M, Rouhi A, Weigel A, Claus R, Weichenhan D, Eichhorst B, Fischer K, Hallek M, Kuchenbauer F, Plass C, Döhner H, Stilgenbauer S, Lichter P, Mertens D

NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib

Int J Cancer. 2018 Jan 15;142(2):322-333 doi: 10.1002/ijc.31057

Hahn M, Bürckert JP, Luttenberger CA, Klebow S, Hess M, Al-Maarri M, Vogt M, Reißig S, Hallek M, Wienecke-Baldacchino A, Buch T, Muller CP, Pallasch CP, Wunderlich FT, Waisman A, Hövelmeyer N

Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling

Leukemia. 2018 Jan;32(1):72-82 doi: 10.1038/leu.2017.168

2017

Fischer K, Hallek M

Optimizing frontline therapy of CLL based on clinical and biological factors

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):338-345

Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Eckart MJ, Vehling-Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner C, Bahlo J, Fischer K, Bentz M, Emmerich B, Döhner H, Hallek M, Stilgenbauer S

Early, risk-adapted treatment with fludarabine in binet stage a chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group

Leukemia. 2017 Dec;31(12):2833-2837

Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S

Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome

Leuk Lymphoma. 2017 Oct 24:1. doi: 10.1080/10428194.2017.1390236. [Epub ahead of print]

Tiao G, Improgo MR, Tausch E, Fernandes SM, Bahlo J, Robrecht S, Fischer K, Hallek M, Stilgenbauer S, Kiezun A, Getz G, Brown JR

Analysis of ITGB2 rare germline variants in chronic lymphocytic leukemia

Blood. 2017 Nov 30;130(22):2443-2444

Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, von Tresckow J, Maurer C, Bergmann M, Seiler T, Lange E, Kneba M, Stilgenbauer S, Döhner H, Kiehl MG, Jäger U, Wendtner CM, Fischer K, Goede V, Hallek M, Eichhorst B, Hopfinger G

Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukaemia: A meta-analysis by the german CLL study group (GCLLSG)

Leukemia. 2017 Oct;31(10):2251-2253

Scheffold A, Jebaraj BM, Jaramillo S, Tausch E, Steinbrecher D, Hahn M, Böttcher S, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P, Stilgenbauer S

Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial

Br J Haematol. 2017 Oct;179(2):342-346

Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study

Lancet Haematol. 2017 Oct;4(10):e475-e486 doi: 10.1016/S2352-3026(17)30171-0

Krämer I, Stilgenbauer S, Dietrich S, Böttcher S, Zeis M, Stadler M, Bittenbring J, Uharek L, Scheid C, Hegenbart U, Ho A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial

Blood. 2017 Sep 21;130(12):1477-1480

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt TD, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfò L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan Djurasevic T, Catherwood MA, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann CU, Dohner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

Clin Cancer Res. 2017 Sep 1;23(17):5292-5301

Hallek M

Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment

Am J Hematol. 2017 Sep;92(9):946-965

Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen PH, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, P Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Buettner R, Persigehl T, Reinhardt HC

Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia

Nat Commun. 2017 Jul 28;8(1):153

Tiao G, Improgo MR, Kasar S, Poh W, Kamburov A, Landau DA, Tausch E, Taylor-Weiner A, Cibulskis C, Bahl S, Fernandes SM, Hoang K, Rheinbay E, Kim HT, Bahlo J, Robrecht S, Fischer K, Hallek M, Gabriel S, Lander ES, Stilgenbauer S, Wu CJ, Kiezun A, Getz G, Brown JR

Rare germline variants in ATM are associated with chronic lymphocytic leukemia

Leukemia. 2017 Jun 27 [Epub ahead of print]

Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, Call TG, Schwager SM, Ding W, Eichhorst B, Fischer K, Leis JF, Chanan-Khan AA, Hallek M, Slager SL, Kay NE

Arial fibrillation in patients with chronic lymphocytic leukemia (CLL)

Leuk Lymphoma. 2017 Jul;58(7):1630-1639

Hallek M

Role and timing of new drugs in CLL

Hematol Oncol. 2017 Jun;35 Suppl 1:30-32

Göckeritz E, Vondey V, Guastafierro A, Pizevska M, Hassenrück F, Neumann L, Hallek M, Krause G

Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue

Br J Haematol. 2017 Sep;178(6):949-953 doi: 10.1111/bjh.14781. Epub 2017 Jun 1

Al-Sawaf O, Cramer P, Goede V, Hallek M, Pflug N

Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review

Ther Adv Hematol. 2017 Jun;8(6):197-205

Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJ, Boettcher S, Ritgen M, Goede V, Mobasher M, Hallek M

Venetoclax and obinutuzumab in chronic lymphocytic leukemia

Blood. 2017 May 11;129(19):2702-2705

Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Muenzner JK, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M

Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia

Leukemia. 2017 May;31(5):1177-1186

Jerkeman M, Hallek M, Dreyling M, Thieblemont C, Kimby E, Staudt L

Targeting of B-cell receptor signalling in B-cell malignancies

J Intern Med. 2017 Mar 14 doi: 10.1111/joim.12600. [Epub ahead of print]

Al-Sawaf O, Fischer K, Herling CD, Ritgen M, Böttcher S, Bahlo J, Elter T, Stilgenbauer S, Eichhorst BF, Busch R, Elberskirch U, Abenhardt W, Kneba M, Hallek M, Wendtner CM

Alemtuzumab consolidation in chronic lymphocytic leukaemia: A phase I/II multicentre trial

Eur J Haematol. 2017 Mar;98(3):254-262

Reiners KS, Shatnyeva O, Vasyutina E, Bösl T, Hansen HP, Hallek M, Herling M, Pogge von Strandmann E Elke Pogge

Extracellular vesicles released from chronic lymphocytic leukemia cells exhibit a disease relevant mRNA signature and transfer mRNAs to bystander cells

Haematologica. 2017 Mar;102(3):e100-e103

Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial

Leukemia. 2017 Mar;31(3):734-738

Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

Drug Des Devel Ther. 2017 Jan 25;11:295-304

Kutsch N, Busch R, Bahlo J, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Wendtner CM, Maria Fink A, Fischer K, Hallek M, Eichhorst B

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia

Leuk Lymphoma. 2017 Feb;58(2):399-407

2016

Eichhorst B, Hallek M

Prognostication of chronic lymphocytic leukemia in the era of new agents

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):149-155

Al-Sawaf O, Fischer K, Eichhorst B, Hallek M

Targeted Therapy of CLL

Oncol Res Treat. 2016;39(12):768-778

Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, Maurer C, Langerbeins P, Fingerle-Rowson G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Klapper W, Wendtner CM, Fischer K, Hallek M, Eichhorst B, Böttcher S

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group

J Clin Oncol. 2016 Nov 1;34(31):3758-3765

Nguyen PH, Fedorchenko O, Rosen N, Koch M, Barthel R, Winarski T, Florin A, Wunderlich FT, Reinart N, Hallek M

LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia

Cancer Cell. 2016 Oct 10;30(4):610-622

Maurer C, Langerbeins P, Bahlo J, Cramer P, Fink AM, Pflug N, Engelke A, von Tresckow J, Kovacs G, Stilgenbauer S, Wendtner CM, Müller L, Ritgen M, Seiler T, Fischer K, Hallek M, Eichhorst B

Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with chronic lymphocytic leukemia (CLL)

Leukemia. 2016 Oct;30(10):2019-2025

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee

eUpdate – Chronic Lymphocytic Leukaemia Treatment Recommendations

(ESMO) Ann Oncol. 2016 Sep;27(suppl 5):v143-v144

Eichhorst B, Hallek M, Goede V

New treatment approaches in CLL: Challenges and opportunities in the elderly

J Geriatr Oncol. 2016 Sep;7(5):375-82

Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink AM, Eichhorst B, Kreuzer KA, Fischer N, Tausch E, Stilgenbauer S, Böttcher S, Döhner H, Kneba M, Dreyling M, Binder M, Hallek M, Wendtner CM, Bergmann M, Fischer K; German CLL Study Group

Bendamustine and Rituximab in Combination with Lenalidomide in Patients with Chronic Lymphocytic Leukemia

Eur J Haematol. 2016 Sep;97(3):253-60

Louise Freeman C, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S, de Costa CS, Iglesias V, Stilgenbauer S, Gribben J, Hallek M, Goede V

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

Leukemia. 2016 Aug;30(8):1763-6

Vyas M, Schneider AC, Shatnyeva O, Reiners KS, Tawadros S, Kloess S, Köhl U, Hallek M, Hansen HP, Pogge von Strandmann E

Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia

Oncoimmunology. 2016 Jul 15;5(9):e1211220

Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP

Dual TORK/DNA-PK inhibition blocks critical signalling pathways in chronic lymphocytic leukemia

Blood. 2016 Jul 28;128(4):574-83

Herling CD, Klaumünzer M, Krings Rocha C, Altmüller J, Thiele H, Bahlo J, Kluth S, Crispatzu G, Herling M, Schiller J, Engelke A, Tausch E, Döhner H, Fischer K, Goede V, Nürnberg P, Reinhardt HC, Stilgenbauer S, Hallek M, Kreuzer KA

Complex karyotypes, KRAS and POT1 mutations impact outcome in CLL after chlorambucil based chemo- or chemoimmunotherapy

Blood. 2016 Jul 21;128(3):395-404

Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG)

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Lancet Oncol. 2016 Jul;17(7):928-42

The International CLL-IPI working group

An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data

Lancet Oncol. 2016 Jun;17(6):779-90 CLL-IPI Online Calculator

Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Lancet Oncol. 2016 Jun;17(6):768-78

Brown JR, Hallek MJ, Pagel JM

Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?

Am Soc Clin Oncol Educ Book. 2016;35:e387-98

Lilienthal N, Lohmann G, Crispatzu G, Vasyutina E, Zittrich S, Mayer P, Herling CD, Tur MK, Hallek M, Pfitzer G, Barth S, Herling M

A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells

Mol Cancer Ther. 2016 May;15(5):971-84

Cramer P, Langerbeins P, Fischer K, Eichhorst B, Hallek M, Goede V

Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?

Leuk Lymphoma. 2016 May;57(5):987-990

Lilienthal N, Lohmann G, Crispatzu G, Vasyutina E, Zittrich S, Mayer P, Herling CD, Tur MK, Hallek M, Pfitzer G, Barth S, Herling M

A novel recombinant anti-CD22 immunokinase delivers pro-apoptotic activity of death-associated protein kinase (DAPK) and mediates cytotoxicity in neoplastic B-cells

Mol Cancer Ther. 2016 May;15(5):971-84

Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, Kellermann L, Borsi L, Civello D, Mensch A, Bahlo J, Hallek M, Stock S, Fingerle-Rowson G

Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia

Leuk Lymphoma. 2016 May;57(5):1130-9

Pflug N, Kluth S, Vehreschild JJ, Bahlo J, Tacke D, Biehl L, Eichhorst B, Fischer K, Cramer P, Fink AM, von Bergwelt-Baildon M, Stilgenbauer S, Hallek M, Cornely OA, Vehreschild MJ

Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota

Oncoimmunology. 2016 Apr 22;5(6):e1150399

Eichhorst B, Cramer P, Hallek M

Initial therapy of chronic lymphocytic leukemia

Semin Oncol. 2016 Apr;43(2):241-50

Hellmich S, Schreiber N, Fath B, Hallek M

Fortschritt durch vernetzte Strukturen: Herausforderungen für das Kompetenznetz Maligne Lymphome im Zeitalter der Präzisionsmedizin

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Apr;59(4):454-64

Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M

Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL Study Group

Leuk Lymphoma. 2016 Apr;57(4):789-96

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O’Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P

A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study

Leukemia. 2016 Apr;30(4):929-36

Goede V, Busch R, Bahlo J, Chataline V, Kremers S, Müller L, Reschke D, Schlag R, Schmidt B, Vehling-Kaiser U, Wedding U, Stilgenbauer S, Hallek M

Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: Primary results of the CLL9 trial of the German CLL Study Group Leuk Lymphoma. 2016 Mar;57(3):596-603

Cramer P, Eichhorst B, Reinhardt HC, Hallek M

Current strategies to create tailored and risk-adapted therapies for CLL patient

Best Pract Res Clin Haematol. 2016 Mar;29(1):111-121

Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

Blood Cancer J. 2016 Mar 11;6:e404

Cramer P, Hallek M, Eichhorst B

State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia

Oncol Res Treat. 2016;39(1-2):25-32

Langerbeins P, Groß-Ophoff-Müller C, Herling CD

Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia

Oncol Res Treat. 2016;39(1-2):18-24

Frenzel LP, Reinhardt HC, Pallasch CP

Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor Microenvironment

Oncol Res Treat. 2016;39(1-2):9-16

Cramer P, Langerbeins P, Hallek M

Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib

Cancer J. 2016 Jan-Feb;22(1):62-66

Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Lancet Oncol. 2016 Feb;17(2):200-11

Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M

Long term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Blood. 2016 Jan 14;127(2):208-15

Cramer P, Langerbeins P, Eichhorst B, Hallek M

Advances in first-line treatment of chronic lymphocytic leukemia current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG)

Eur J Haematol. 2016 Jan;96(1):9-18

2015

Kirsten Fischer, Anna-Maria Fink, Helen Bishop, Mark Dixon, Jasmin Bahlo, Michael Y. Choi, Robert Weinkove, K. Sue Robinson, Martin Dreyling, Till Seiler, Stephen Opat, Carolyn Owen, Javier Lopez Sr., Nadine Kutsch, Eugen Tausch, Matthias Ritgen, Rod A. Humerickhouse, Kathryn Humphrey, Michael K. Wenger, Valentin Goede, Barbara Eichhorst, Clemens-Martin Wendtner, Stephan Stilgenbauer, Thomas J. Kipps and Michael Hallek

Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions

(ASH Abstract) Blood 2015 Dec 03;126(23):496

Cramer P, Isfort S, Bahlo J, Stilgenbauer S, Döhner H, Bergmann M, Stauch M, Kneba M, Lange E, Langerbeins P, Pflug N, Kovacs G, Goede V, Fink AM, Elter T, Fischer K, Wendtner CM, Hallek M, Eichhorst B

Outcome of advanced chronic lymphocytic leukemia following different firstline- and relapse-therapies: A metaanalysis of five prospective trials of german CLL study group (GCLLSG)

Haematologica. 2015 Nov;100(11):1451-9

Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner CM, Klein C, Liu N, Hallek M, Frenzel LP, Krause G

Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells

Int J Cancer. 2015 Nov 1;137(9):2234-42

Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S, Wu CJ

Mutations driving CLL and their evolution in progression and relapse

Nature. 2015 Oct 22;526(7574):525-30

Goede V, Hallek M

Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope

Drugs Aging. 2015 Nov;32(11):877-86

Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner CM, Klein C, Liu N, Hallek M, Frenzel LP, Krause G

Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells

Int J Cancer. 2015 Nov 1;137(9):2234-42

Chakupurakal G, Leitzke S, Langerbeins P, Schiller J, Schneider PM, Holtick U, Shimabukuro-Vornhagen A, Theurich S, Chemnitz J, Hallek M, von Bergwelt-Baildon M, Scheid C

Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality-a single institution experience

Ann Hematol. 2015 Oct;94(10):1717-25

Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Ann Oncol. 2015 Sep;26 Suppl 5:v78-v84

2014 – 2010

2014

Stilgenbauer S, Cymbalista F, Leblond V, Delmer A, Ibach S, Choquet S, Dartigeas C, Cazin B, Tournilhac O, Pegourie B, Seiler TM, Sökler M, Zirlik K, Alt J, Huber H, Bloehdorn J, Tausch E, Zenz T, Hallek M, Schetelig J, Dreger P, Döhner H

Alemtuzumab combined with dexamethasone, followed by alemtuzumab maintenance or Allo-SCT in “ultra High-risk” CLL: final results from the CLL2O phase II study

Blood. 2014;124:1991

Langerbeins P, Busch R, Anheier N, Dürig J, Bergmann M, Goebeler ME, Hurtz HJ, Stauch MB, Stilgenbauer S, Döhner H, Fink AM, Cramer P, Fischer K, Wendtner CM, Hallek M, Eichhorst B

Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation

Am J Hematol. 2014 Dec;89(12):E239-43

Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M, Moreno C, Stilgenbauer S, Montserrat E; European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Blood. 2014 Dec 18;124(26):3841-9

Pallasch CP, Hallek M

Incorporating targeted agents into future therapy of chronic lymphocytic leukemia

Semin Hematol. 2014 Jul;51(3):235-48

Weisser M, Yeh RF, Duchateau-Nguyen G, Palermo G, Nguyen TQ, Shi X, Stinson SY, Yu N, Dufour A, Robak T, Salogub GN, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Fischer K, Fink AM, Hallek M, Bloehdorn J, Busch R, Benner A, Döhner H, Valente N, Wenger MK, Stilgenbauer S, Dornan D

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Blood. 2014 Jul 17;124(3):420-5

Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Blood. 2014 Jul 3;124(1):49-62

Goede V, Cramer P, Busch R, Bergmann M, Stauch M, Hopfinger G, Stilgenbauer S, Doehner H, Westermann A, Wendtner CM, Eichhorst B, Hallek M

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials

Haematologica. 2014 Jun;99(6):1095-100

Ghia P, Hallek M

Management of chronic lymphocytic leukemia

Haematologica. 2014 Jun;99(6):965-972

Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K, Bühler A, Böttcher S, Ritgen M, Kneba M, Winkler D, Tausch E, Hoth P, Edelmann J, Mertens D, Bullinger L, Bergmann M, Kless S, Mack S, Jäger U, Patten N, Wu L, Wenger MK, Fingerle-Rowson G, Lichter P, Cazzola M, Wendtner CM, Fink AM, Fischer K, Busch R, Hallek M, Döhner H

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Blood. 2014 May 22;123(21):3247-54

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

N Engl J Med. 2014 Mar 20;370(12):1101-10

2013

Cramer P, Bahlo J, Eichhorst B, Fischer K, Hallek M

Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual

Leuk Res. 2013 Dec 1. pii: S0145-2126(13)00416-5

Hallek M

Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies

Hematology Am Soc Hematol Educ Program. 2013;2013:138-50 Blood. 2013 Nov 28;122(23):3723-34

Maurer C, Hallek M

Chronische lymphatische Leukämie

Dtsch Med Wochenschr. 2013 Oct;138(42):2153-66

Hallek M

Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

Am J Hematol. 2013 Sep;88(9):803-16

Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S, Busch R, Hallek M

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

Leukemia. 2013 Sep;27(9):1949-52

Göbel M, Eisele L, Möllmann M, Hüttmann A, Johansson P, Scholtysik R, Bergmann M, Busch R, Döhner H, Hallek M, Seiler T, Stilgenbauer S, Klein-Hitpass L, Dührsen U, Dürig J

Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia

PLoS One. 2013 Aug 23;8(8):e72107

Schnaiter A, Paschka P, Rossi M, Zenz T, Bühler A, Winkler D, Cazzola M, Döhner K, Edelmann J, Mertens D, Kless S, Mack S, Busch R, Hallek M, Döhner H, Stilgenbauer S

NOTCH1, SF3B1 and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

Blood. 2013 Aug 15;122(7):1266-70

Cramer P, Fink AM, Busch R, Eichhorst B, Wendtner C, Pflug N, Langerbeins P, Bahlo J, Goede V, Schubert F, Döhner H, Stigenbauer S, Dreger P, Kneba M, Böttcher S, Mayer J, Hallek M, Fischer K

Second-line Therapies of Patients initially treated with Fludarabine and Cyclophosphamide (FC) or Fludarabine, Cyclophosphamide and Rituximab (FCR) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)

Leuk Lymphoma. 2013 Aug;54(8):1821-2

Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, Stilgenbauer S, Döhner H, Kandler G, Eichhorst B, Hallek M, Herling M

Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia

Cancer. 2013 Jun 15;119(12):2258-67

Goede V, Fischer K, Busch R, Jaeger U, Dilhuydy MS, Wickham N, De Guibert S, Ritgen M, Langerak AW, Bieska G, Engelke A, Humphrey K, Wenger M, Hallek M

Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in

Leukemia. 2013 Apr;27(5):1172-4

Dreger P, Schnaiter A, Zenz T, Böttcher S, Rossi M, Paschka P, Bühler A, Dietrich S, Busch R, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Stilgenbauer S

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Blood. 2013 Apr 18;121(16):3284-8

Hallek M, Knauf W, Dreyling M, Trümper L

Aktuelle und künftige Indikationen mit Bendamustin: chronische lymphatische Leukämie, indolente Lymphome, Mantelzell-Lymphome und diffuse großzellige B-Zell-Lymphome

Onkologie. 2013;36 Suppl 1:11-8

Stilgenbauer S, Hallek M

Chronische lymphatische Leukämie: Therapie und genetisches Risikoprofil

Internist (Berl). 2013 Feb;54(2):164-70

2012

Elter T, James R, Busch R, Winkler D, Ritgen M, Böttcher S, Kahl C, Gassmann W, Stauch M, Hasan I, Staib P, Fischer K, Fink AM, Bahlo J, Bühler A, Döhner H, Wendtner CM, Stilgenbauer S, Engert A, Hallek M writtrn on behalf of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG)

Fludarabine and cyclophosphamide in combination with alemtuzumab (FCCam) in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia

Leukemia. 2012 Dec;26(12):2549-52

Edelmann J, Holzmann K, Miller F, Winkler D, Bühler A, Zenz T, Bullinger L, Kühn MW, Gerhardinger A, Bloehdorn J, Radtke I, Su X, Ma J, Pounds S, Hallek M, Lichter P, Korbel J, Busch R, Mertens D, Downing JR, Stilgenbauer S, Döhner H

High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations

Blood. 2012 Dec 6;120(24):4783-94

Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pflüger KH, Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Bühler A, Winkler D, Kreuzer KA, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF, Hallek M, Stilgenbauer S, Wendtner CM

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

J Clin Oncol. 2012 Sep 10;30(26):3209-16

Köppler H, Fuss H, Hurtz HJ, Knigge O, Losem C, Reschke D, Schmitz S, Weide R, Weiß J, Hallek M; for the GCLLSG

Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG)

Br J Haematol. 2012 Jul;158(2):238-41

Isfort S, Cramer P, Hallek M

Novel and emerging drugs for chronic lymphocytic leukemia

Curr Cancer Drug Targets. 2012 Jun;12(5):471-83

Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M, Schmitz N, Hallek M, Stilgenbauer S

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the GCLLSG CLL3 trial

Blood. 2012 May 24;119(21):4851-4859

Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S.

Risk categories and refractory CLL in the era of chemoimmunotherapy

Blood. 2012 May 3;119(18):4101-7

Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner CM, Eichhorst BF, Döhner H, Hallek MJ, Kneba M.

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

J Clin Oncol. 2012 Mar 20;30(9):980-8

Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, Engert A.

Alemtuzumab for patients with chronic lymphocytic leukaemia

Cochrane Database Syst Rev. 2012 Feb 15;2:CD008078

2011

Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the german chronic lymphocytic leukemia study group

J Clin Oncol. 2011 Sep 10;29(26):3559-66

Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M; ESMO Guidelines Working Group

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Ann Oncol. 2011 Sep;22 Suppl 6:vi50-4

Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Blood. 2011 Feb 10;117(6):1817-21

Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation

Blood. 2011 Feb 3;117(5):1516-21

Hallek M, Pflug N

State of the art treatment of chronic lymphocytic leukaemia

Blood Rev. 2011 Jan;25(1):1-9

Cramer P, Hallek M.

Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

Nat Rev Clin Oncol. 2011 Jan;8(1):38-47. Review

2010

Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S

TP53 mutation and survival in chronic lymphocytic leukemia

J Clin Oncol. 2010 Oct 10;28(29):4473-9

Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, HasenkampJ, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M,Kneba M, Schmitz N, Stilgenbauer S.

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial

Blood. 2010 Oct 7;116(14):2438-47

Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Lancet. 2010 Oct 2;376(9747):1164-74

Schweighofer CD, Wendtner CM.

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

Onco Targets Ther. 2010 Jun 24;3:53-67

2009 – 2005

2009

Hallek M.

State-of-the-art treatment of chronic lymphocytic leukemia

Hematology Am Soc Hematol Educ Program. 2009:440-9. Review

Dreger P.

Allotransplantation for chronic lymphocytic leukemia

Hematology Am Soc Hematol Educ Program. 2009:602-9. Review.

Böttcher S, Stilgenbauer S, Busch R, Brüggemann M, Raff T, Pott C, Fischer K, Fingerle-Rowson G, Döhner H, Hallek M, Kneba M, Ritgen M.

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patientsafter rituximab-containing immunochemotherapy: a comparative analysis

Leukemia. 2009 Nov;23(11):2007-17

Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhofer N, Rohrberg R, Soling U, Burkhard O, Westermann A, Goede V, Schweighofer CD, Fischer K, Fink AM, Wendtner CM, Brittinger G, Dohner H, Emmerich B, Hallek M; German CLL Study Group (GCLLSG)

First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Blood 2009 Oct 15;114(16):3382-91

Zenz T, Häbe S, Denzel T, Mohr J, Winkler D, Bühler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Döhner H, Stilgenbauer S

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

Blood. 2009 Sep 24;114(13):2589-97

Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H; German Chronic Lymphocytic Leukemia Study Group

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

J Clin Oncol. 2009 Aug 20;27(24):3994-4001

Eichhorst B, Goede V, Hallek M.

Treatment of elderly patients with chronic lymphocytic leukemia

Leuk Lymphoma. 2009 Feb;50(2):171-8

Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

Br J Haematol. 2009 Jan;144(1):95-8

2008

Ritgen M, Böttcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S, Humpe A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P; German CLL Study Group

Quantitative MRD monitoring identifies distinct GVLresponse patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial

Leukemia. 2008 Jul;22(7):1377-86

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia.

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the InternationalWorkshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Blood. 2008 Jun 15;111(12):5446-56
(Erratum in Blood. 2008 Dec 15;112(13):5259)

Hallek M; German CLL Study Group

Prognostic factors in chronic lymphocytic leukemia

Ann Oncol. 2008 Jun;19 Suppl 4:iv51-3

2007

Eichhorst BF, Busch R, Stauch M, Bergmann M, Ritgen M, Kranzhöfer N, Schweighofer CD, Fischer K, Fink A-M, Cramer P, Goede V, Wendtner CM, Hallek M, GCLLSG

No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG)

Blood (ASH Annual Meeting Abstracts) 2007 Nov; 110(11): Abstract #629

Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M; German CLL Study Group.

Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group

J Clin Oncol. 2007 May 1;25(13):1722-31

Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M; German CLL Study Group (GCLLSG).

Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy

Br J Haematol. 2007 Jan;136(1):63-72

2006

Bilban M, Heintel D, Scharl T, Woelfel T, Auer MM, Porpaczy E, Kainz B, Krober A, Carey VJ, Shehata M, Zielinski C, Pickl W, Stilgenbauer S, Gaiger A, Wagner O, Jager U; German CLL Study Group.

Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression

Leukemia. 2006 Jun;20(6):1080-8

Moosig F, Schoch R, Kneba M.

Die T-Large Granular Lymphocyte Leukämie (T-LGL-Leukämie): Eine wichtige Differenzialdiagnose zum Felty-Syndrom

Z Rheumatol. 2006; 65(6): 447 – 451

Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jager U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Dohner H, Brittinger G, Emmerich B, Hallek M; German CLL Study Group.

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

Blood 2006; 107(3): 885 – 891

2005

Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek MJ; German CLL Study Group

Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group

Haematologica. 2005 Oct;90(10):1357-64

Heintel D, Kienle D, Shehata M, Krober A, Kroemer E, Schwarzinger I, Mitteregger D, Le T, Gleiss A, Mannhalter C, Chott A, Schwarzmeier J, Fonatsch C, Gaiger A, Dohner H, Stilgenbauer S, Jager U.

High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia

Leukemia 2005; 19: 1216 – 1223

2004 – 2000

2004

Heintel D, Kroemer E, Kienle D, Schwarzinger I, Gleiss A, Schwarzmeier J, Marculescu R, Le T, Mannhalter C, Gaiger A, Stilgenbauer S, Dohner H, Fonatsch C, Jager U; German CLL Study Group.

High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia

Leukemia 2004; 18(4): 756 – 62

Dreger P; German CLL Study Group; EBMT.

Transplantation strategies in chronic lymphocytic leukemia: current concepts of the German CLL Study Group and the EBMT

Ann Hematol. 2004; 83 Suppl 1: S68 – 70

Hallek M, Eichhorst BF

Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia

Hematol J. 2004; 5 Suppl 1: S20 – 30

Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Dohner H, Kneba M, Emmerich B, Hallek M; German CLL Study Group (GCLLSG)

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)

Leukemia. 2004; 18(6): 1093 – 101

Hallek M, Bergmann M, Emmerich B

Chronic lymphocytic leukaemia: up-dated recommendations on diagnosis and treatment

Onkologie. 2004; 27(1): 97 – 104

Dreger P, Stilgenbauer S, Benner A, Ritgen M, Krober A, Kneba M, Schmitz N, Döhner H.

The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status

Blood 2004; 103(7): 2850 – 2858

2003

Hallek M, Bergmann M, Goede V, Fingerle-Rowson G, Schweighofer C, Schmitt B, Wendtner CM, Emmerich B

Current concepts in chronic lymphocytic leukemia. Better chances for young patients

MMW Fortschr Med. 2003; 145(27-28): 46-9

2002

Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A; German CLL Study Group

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

Blood. 2002 Nov 1;100(9):3115-20

Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A, Pasold R, Schlag R, Hopfinger G, Hiddemann W, Emmerich B, Hallek M

Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia

Clin Lymphoma. 2002; 3(1): 26 – 35

Hallek M, Bergmann M, Emmerich B für die Deutsche CLL-Studiengruppe

Chronische lymphatische Leukämie: Aktualisierte Vorschläge zu Diagnostik und Therapie

Dt. Ärzteblatt 2002; Jg.99 (Heft 19): A 1294 – A1301

Stilgenbauer S, Bullinger L, Lichter P and Döhner H. and the German CLL Study Group

Genetics of chronic lymphotic leukemia: genomic aberrations and VH gene mutation status in pathogenesis andclinical course

Leukemia 2002; 16(6): 993 – 1007

2001

Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B; German Chronic Lymphocytic Leukemia Study Group

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

Blood. 2001 Sep 1;98(5):1326-1331

Hallek M, Schmitt B, Wilhelm M, Busch R, Krober A, Fostitsch HP, Sezer O, Herold M, Knauf W, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Dohner H, Thiel E, Hiddemann W, Brittinger G, Emmerich B; German Chronic Lymphocytic Leukaemia Study Group

Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

Br J Haematol. 2001 Aug;114(2):342-348

Hallek M, Buening H, Ried M, Hacker U, Kurzeder C, Wendtner CM

Grundlagen der Gentherapie -Prinzipien und Stand der Entwicklung

Internist 2001; 42(10): 1306 – 1313

2000

Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P

Genomic aberrations and survival in chronic lymphocytic leukemia

N Engl J Med. 2000 Dec 28;343(26):1910-6

von Bubnoff N, Adler S, Danhauser-Riedl S, Kamp T, Nerl C, Emmerich B, Hallek M

The activation of intracellular tyrosine kinases by interferon-alpha (IFNalpha) correlates with its antiproliferative activity in B-lymphoid cell lines, but not in B-cell chronic lymphocytic leukaemia patients

Ann Hematol 2000; 79(3): 119-126

1999 – 1996

1999

Wendtner CM, Schmitt B, Wilhelm M, Dreger P, Montserrat E, Emmerich B, Hallek M

Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy

Ann Oncol. 1999; 10(5): 505 – 509

Meinhardt G, Wendtner CM, Hallek M

Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival

J Mol Med 1999; 77(2): 282 -293

Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M

CD40-Activated B-Cell Chronic Lymphocytic Leukemia Cells for Tumor Immunotherapy: Stimulation of Allogeneic Versus Autologous T Cells Generates Different Types of Effector Cells

Blood 1999; 93(6): 1992 – 2002

Hallek M, Langenmayer I, Nerl C, Knauf WU, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I Thiel E, Emmerich B

Elevated serum thymidine kinase levels identify a subgroup at high risk of disease-progressionin early, non-smoldering chronic lymphocytic leukemia.

Blood 1999; 93(5): 1732 – 1737

1997

Hallek M, Kuhn-Hallek I, Emmerich B

Prognostic factors in chronic lymphocytic leukemia.

Leukemia 1997; 11 (Suppl.2): S4 – S13

1996

Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, Schick H-D, Kuhn-Hallek I, Emmerich B

Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progressionfree survival in chronic lymphocytic leukemia and immunocytoma.

Leuk Lymphoma 1996; 22(5-6): 439 – 447

Langenmayer I, Knauf W, Nerl C, Dempster S, Hallek M, Adorf D, Dietzfelbinger H, Busch R, Ziegler-Heitbrock HWL, Thiel E, Emmerich B

Interferon-alpha-2b (IFN alpha) for early-phase lymphocytic leukemia with high risk disease-progression: results of a randomized multicenter study.

Br J Haematol. 1996; 94(2): 362 – 369

NEWS

Ziel ist die konsequente Optimierung der Therapie der CLL.

Übersicht

2025 – 2020

2025

Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOP

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Efficacy of MRD-triggered Anti-CD20 Retreatment in Patients with High-Risk Chronic Lymphocytic Leukemia: A Case Series

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Acalabrutinib treatment in Older (≥80y) and/or Frail Patients with CLL – Primary Endpoint Analysis of the CLL-Frail Trial

Surrogate endpoints in mature B-cell neoplasms – meaningful or misleading?

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia

Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial.

2024

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia

Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combination

Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry

The role of trephine bone marrow biopsies in the era of measurable residual disease-Results from the CLL10 trial of the German CLL Study Group (GCLLSG)

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.

Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.

Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.

Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease

2023

Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.

Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

First line therapy of CLL.

Importance of MRD in the era of targeted therapies in CLL

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.

Long-term efficacy of ibrutinib-venetoclax for first-line treatment in chronic lymphocytic leukaemia

Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.

Overcoming Resistance in Chronic Lymphocytic Leukemia – Maybe Less is More?

Role of the tumor microenvironment in CLL pathogenesis.

Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease

2022

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.

KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.

SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia.

The role of minimal residual disease in chronic lymphocytic leukemia.

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.

COVID-19 in patients with hematologic malignancy.

The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia.

Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial

Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis

Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.

Management of front line chronic lymphocytic leukemia.

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

Molecular map of chronic lymphocytic leukemia and its impact on outcome

Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older.

2021

TP53 mutations in CLL: does frequency matter?

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.

Acalabrutinib monotherapy in patients with Richter transformation.

Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies

The CLL12 trial: Ibrutinib versus placebo in treatment-naïve, early stage chronic lymphocytic leukemia.

Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany.

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.